Compound 3(University of Salerno)(Compound 3(University of Salerno)) - 药物靶点：PTGES2_在研适应症：胰腺导管腺癌，急性髓性白血病_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

PTGES2

作用方式

调节剂

作用机制

PTGES2 modulators(prostaglandin E synthase 2 modulators)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [1]

在研适应症

胰腺导管腺癌急性髓性白血病

非在研适应症-

原研机构

University of Salerno

在研机构

Sun Pharma Advanced Research Company Ltd.

Gyala Therapeutics SL初创企业

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Compound 3(University of Salerno) 相关的临床结果

登录后查看更多信息

100 项与 Compound 3(University of Salerno) 相关的转化医学

登录后查看更多信息

100 项与 Compound 3(University of Salerno) 相关的专利（医药）

登录后查看更多信息

1

项与 Compound 3(University of Salerno) 相关的文献（医药）

1998-10-01·IUBMB Life

Redox regulation of signal transduction in vascular smooth muscle cells: Thiol oxidizing agents induced phospholipase D

Article

作者: Anwar S. Abd‐Elfattah ; Mahmoud A. Mahgoub ; Mohiuddin M. Taher

AbstractDecrease in intracellular thiols leads to oxidative stress and thus may cause alterations in the activity of redox‐sensitive enzymes required for signal transduction. Here, we report that, N‐ethylmaleimide and phenylarsine oxide, which are known to oxidize free thiols as well as protein thiols, induced phosphatidyl ethanol generation in the micromolar range suggesting activation of phospholipase D in vascular smooth muscle cells. These agents also induced significant phosphatidic acid and diacylglycerol generation without causing protein kinase C activation. Phenylarsine oxide and N‐ethyl maleimide induced phosphotipase D activation is protein kinase C independent as it was not inhibited by compound‐3 and bisindolylmaleimide, potent protein kinase C inhibitors. Tyrosine kinase inhibitor herbimycin A by itself activated PLD, but inhibited the phospholipase D activation by phenytarsine oxide and N‐ethylmaleimide. These results suggest that oxidation of the cellular thiols activates phospholipase D independent of protein kinase C.

100 项与 Compound 3(University of Salerno) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺导管腺癌	临床前	-	Sun Pharma Advanced Research Company Ltd.	2022-12-13
急性髓性白血病	临床前	-	Gyala Therapeutics SL初创企业	2022-12-11